Google Search

Search

Already a Member ?

Best Business Opportunities in Algeria, Africa - Identification and Selection of right Project, Thrust areas for Investment, Industry Startup and Entrepreneurship Projects

Reasons why you should start a Business in Algeria

Algeria is Africa's largest country, and its economy is one of the world's fastest-growing. According to a report released by The Economist Intelligence Unit, Algeria's rapid growth and young population are two of the most important factors that make it an ideal environment to start a business today, as well as in the coming years until 2025, when Algeria will become more attractive than Egypt, Turkey, Morocco, and Jordan combined (EIU). Here are eight compelling reasons to launch a business in Algeria.

Market Size

Algeria has a huge and young population, with more than 40% of the population under the age of 25. Workers from neighbouring countries such as Morocco, Tunisia, and Mali have a great desire to work in the country. And those aren't just hypothetical possibilities: an estimated five million Algerians live outside of their homeland, according to BBC News (most of them in France). Furthermore, Algeria is predicted to have some of Africa's fastest economic development in the coming years. As a result, it will be a hotbed for international investment—as well as entrepreneurs.

Business-Friendly Policies and Government Initiatives;

Algeria attracts foreign enterprises for a variety of reasons. There is no corporate income tax or capital gains tax, for starters. Algeria has one of the most transparent legal and regulatory regimes in Africa, according to Invest in Algeria. In addition, the country provides access to a big market of over 30 million people, with an average annual growth rate of 5% over the last decade. South Africa, India, China, and Brazil are among the 38 nations with whom the country has free trade agreements.This means that businesses will be able to import items from these nations without having to pay tariffs. It also makes it simpler for Algerian businesses to export their goods internationally. Finally, dividends paid by Algerian enterprises are not subject to withholding tax. Furthermore, international investors have the option to repatriate their gains at any moment. In short, starting a business in Algeria appears to be simple and successful.

Business Opportunities in Algeria

Algeria attracts foreign enterprises for a variety of reasons. There is no corporate income tax or capital gains tax, for starters. Algeria has one of the most transparent legal and regulatory regimes in Africa, according to Invest in Algeria. In addition, the country provides access to a big market of over 30 million people, with an average annual growth rate of 5% over the last decade. South Africa, India, China, and Brazil are among the 38 nations with whom the country has free trade agreements.

What are the Natural Resources in Algeria?

Algeria is blessed with abundant natural resources. Oil, gas, phosphates, and iron ore, according to the government, are among them. There are also marble, asbestos, salt, and gypsum resources. Algerian economic policy aims to diversify its economy away from its reliance on petroleum extraction.

What businesses are successful in Algeria?

This means that businesses will be able to import items from these nations without having to pay tariffs. It also makes it simpler for Algerian businesses to export their goods internationally. Finally, dividends paid by Algerian enterprises are not subject to withholding tax. Furthermore, international investors have the option to repatriate their gains at any moment. In short, starting a business in Algeria appears to be simple and successful.

Is Algeria good for Business?

Algeria, one of Africa's fastest-growing economies and one of the continent's safest and nicest countries, is fundamentally an African country. As investors look for chances, the Maghreb region continues to grow in prominence. Natural resources (oil and gas, agriculture) drive the economy, thus there are lots of prospects for international companies looking to enter the market.

Algeria Industrial Infrastructure;

Algeria's infrastructure and logistics sectors are typically well-developed. Furthermore, the government has made significant investments in transportation, particularly rail and road systems. The government has also prioritised the development of energy distribution and supply networks. Despite the fact that energy is available throughout much of the country, power outages do occur in urban areas at certain times or seasons. In Algiers, for example, rolling blackouts are common in July and August due to excessive demand for air conditioning. Despite these hurdles, there are several opportunities for corporations interested in investing in Algeria's infrastructure development projects as part of their overall business plan.

What are the steps for Starting a Business in Algeria?

Starting a business from the ground up involves much research, planning, and preparation. Take some time to consider all of your choices for starting your new business before you even consider developing your business plan. We've detailed five simple steps to help you get your business off the ground in Algeria.

It's also crucial to keep in mind that, while these are our recommendations for starting a business in Algeria, there is no one-size-fits-all method to beginning a new firm. Before taking any activities relating to your firm, it is usually a good idea to consult with an attorney who specialises in small businesses and startups.

Industrial Growth

Algeria's economy is diversifying, and mining, construction materials, and hydrocarbons are all growing in importance. Expats will find various career options in these fields. Algeria's labour force numbers more than 40 million people, with an 11 percent unemployment rate. Petroleum, gas, chemicals, and plastics, as well as food processing and electric generation, are the most important industries. Railroads, roadways, and airports are among the government's transportation infrastructure investments. Minerals such as iron ore, lead, and zinc are mined in northern Algeria, in addition to oil and natural gas reserves. Industry accounted for 24% of GDP in 2015, while services accounted for 75% of GDP.

We can provide you detailed project reports on the following topics. Please select the projects of your interests.

Each detailed project reports cover all the aspects of business, from analysing the market, confirming availability of various necessities such as plant & machinery, raw materials to forecasting the financial requirements. The scope of the report includes assessing market potential, negotiating with collaborators, investment decision making, corporate diversification planning etc. in a very planned manner by formulating detailed manufacturing techniques and forecasting financial aspects by estimating the cost of raw material, formulating the cash flow statement, projecting the balance sheet etc.

We also offer self-contained Pre-Investment and Pre-Feasibility Studies, Market Surveys and Studies, Preparation of Techno-Economic Feasibility Reports, Identification and Selection of Plant and Machinery, Manufacturing Process and or Equipment required, General Guidance, Technical and Commercial Counseling for setting up new industrial projects on the following topics.

Many of the engineers, project consultant & industrial consultancy firms in India and worldwide use our project reports as one of the input in doing their analysis.

We can modify the project capacity and project cost as per your requirement.
We can also prepare project report on any subject as per your requirement.

Page 15 of 56 | Total 551 projects in this category
« Previous   Page 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 .... 55 56   Next »

Add multiple items to inquiry
Select the items and then press Add to inquiry button

Select all | Clear all Sort by

API Production. Manufacturing of Active Pharma Ingredients (API), Cephalexin, Ampicillin Trihydrate, Ibuprofen and Paracetamol.

API Production. Manufacturing of Active Pharma Ingredients (API), Cephalexin, Ampicillin Trihydrate, Ibuprofen and Paracetamol. API (Active Pharmaceutical Ingredient) means the active ingredient which is contained in medicine. For example, an active ingredient to relieve pain is included in a painkiller. This is called API. A small amount of the active ingredient has an effect, so only a tiny part of the active ingredient is contained in medicine. Related Projects:- Active Pharma Ingredients (api) The API form that is used in a formulation is often the most thermodynamically stable crystalline form. As such, the phenomenon of hydrogen bonding in combination with there being many functional groups on the API usually results in the available crystalline form being a hydrate. Related Books: - Pharmaceutical, Drugs, Proteins Technology Handbooks Ampicillin is used to treat infections by many Gram-positive and Gram-negative bacteria. It was the first "broad spectrum" penicillin with activity against Gram-positive bacteria, including Streptococcus pneumonia, Streptococcus pyogenic, some isolates of Staphylococcus aureus (but not penicillin-resistant or methicillin-resistant strains), Trueperella, and some Enterococcus. Paracetamol is used for the relief of mild to moderate pain. The use of the intravenous form for short-term pain in people in the emergency department is supported by limited evidence. In adults it appears to be useful for migraines, tension headaches, perineal pain after childbirth, and kidney stone pain. Related Projects: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates Ibuprofen is a medication in the nonsteroidal anti-inflammatory drug class that is used for treating pain, fever, and inflammation. This includes painful menstrual periods, migraines, and rheumatoid arthritis. It may also be used to close a patent ductus arteriosus in a premature baby. Market Outlook The production-linked incentive scheme - which accounts for INR0.9 billion of planned outlay - offers an incentive of up to 20% of sales for fermentation based products and up to 10% for chemical synthesis-based products for the next eight to nine years. This should help to bridge the price gap and make domestic production more competitive. The government has also allocated USD0.4 billion under the capex assistance scheme to fund up to 90% of the investment need to build common infrastructure facilities in three bulk drug parks. We believe this will aid the investment decisions of Indian pharma companies, particularly in the current environment where the focus in on conserving cash. Related Videos: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Pharmaceutical Drugs, Pharma Drug Ingredients Intermediates, Pharmaceutical Bulk Drugs The increasing incidence of chronic diseases, growing importance of generics, and the increasing uptake of biopharmaceuticals are some of the major factors driving the growth of the global APIs market. On the other hand, the unfavorable drug price control policies across various countries and the increasing penetration of counterfeit drugs are expected to restrain the growth of this market in the coming years. Active pharmaceutical ingredients are an active ingredient of any drug or tablet, which possesses medicinal properties. Some drugs with combined therapy have many active ingredients to treat different disorders. Related Videos: - Active Pharma Ingredients (API) - Global Market Estimated to Reach US$ 21.9 billion by 2023 Higher Growth in the APAC Active Pharmaceutical Ingredients Market Healthcare spending has witnessed continued growth for some time now. Even though the proportion of healthcare spending in the APAC region is comparatively low, the growth rate in this strategic region has outpaced that of mature markets in North America and Europe. Rising healthcare spending has led to quality healthcare becoming accessible along with a higher demand for pharmaceutical products across APAC. The pharmaceuticals consumed here are mostly produced in onshore manufacturing units. Furthermore, contract manufacturing organizations are key outsourcing allies for pharmaceutical companies that supply their wares to North America and Europe. Books:- BOOKS & DATABASES Huge investment promises from different countries predict a bright future for India. It has a well-developed administration and an independent judicial system with an ever-growing consumer base. It has a huge pool of hard-working skilled workers in all fields. The government has set up tax and non-tax incentives to establish new industrial entities in specific sectors, which include energy, ports, highways, electronics, and software. Related Videos:- Investment Opportunities in API Bulk Drugs & Intermediates Manufacturing Unit The global active pharmaceutical ingredients market has been broadly segmented based on manufacturer, APIs, drug, therapeutic, and region. In terms of manufacturer, the global market has been classified into in-house API manufacturing and API contract manufacturing. The increasing incidence of chronic diseases, growing importance of generics, and the increasing uptake of biopharmaceuticals are some of the major factors driving the growth of the global APIs market. On the other hand, the unfavorable drug price control policies across various countries and the increasing penetration of counterfeit drugs are expected to restrain the growth of this market in the coming years. Related Videos:- Manufacturing Business Ideas in Pharmaceutical Industry Role of Government towards API The coronavirus outbreak disrupting supply of active pharmaceutical ingredients (APIs) and medical devices from China to India, the government has come out with four schemes worth Rs 13,760 crore to encourage manufacturing of bulk drugs and medical devices in the country and their exports. On March 21, the Union Cabinet under the chairmanship of Prime Minister Narendra Modi had approved an expenditure of Rs. 9,940 crore and Rs. 3,820 crore for APIs and medical devices, respectively. The Cabinet also approved a scheme on promotion of bulk drug parks for financing common infrastructure facilities in three bulk drug parks with financial implication of Rs. 3,000 crore for next five years. The government will give grants-in-aid to states with a maximum limit of Rs. 1,000 crore per bulk Drug Park. Parks will have common facilities such as solvent recovery plant, distillation plant, power and steam units, common effluent treatment plant etc. Related Projects:- Startup Opportunities in Active Pharma Ingredients The government further approved production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/drug intermediates and APIs in the country with financial implications of Rs. 6,940 crore for next eight years. Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. Rate of incentive will be 20 per cent (of incremental sales value) for fermentation based bulk drugs and 10 per cent for chemical synthesis based bulk drugs. The PLI scheme will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over eight years. Market Research Reports:- India Active Pharmaceutical Ingredient (API) The drug industry has welcomed the incentives offered by the government to promote API units in India. Besides APIs, the Cabinet also approved the scheme for promotion of medical device parks in the country in partnership with the states. A maximum grant-in-aid of Rs. 100 crore per park will be provided to the states. It will have financial implications of Rs. 400 crore. The PLI scheme for promoting domestic manufacturing of medical devices will have financial implications of Rs. 3,420 crore for next five years. Market Research:- Market Research Reports Medical device is a growing sector and its potential for growth is the highest among all sectors in the healthcare market. It is valued at Rs. 50,026 crore for 2018-19 and is expected to reach to Rs. 86,840 crore by 2021-22. India depends on imports up to an extent of 85 per cent of total domestic demand of medical devices. Related Projects: - Investment Opportunities in API Bulk Drugs & Intermediates Manufacturing Unit Union Cabinet scheme on Promotion of Bulk Drug Parks • The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years. • Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6,940 crore for next eight years. Related Projects:- Active Pharma Ingredients (api) (cephalexin, Ampicillin Trihydrate, Ibuprofen And Paracetamol) Details: Promotion of Bulk Drug Parks • Decision is to develop 3 mega Bulk Drug parks in India in partnership with States. • Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park. • Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc. • A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years. Related Projects: - Active Pharma Ingredients (API) Production Linked Incentive Scheme • Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. • Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. • Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs. • A sum of Rs. 6,940 crore has been approved for next 8 years. Projects: - Project Reports & Profiles For More Details, Click Here: - Key players Alpha Remedies Ltd. Ankur Drugs & Pharma Ltd. Aurobindo Pharma Ltd. Cian Healthcare Ltd Cipla Ltd. Dr. Reddy'S Laboratories Ltd. Farmson Pharmaceutical Gujarat Pvt. Ltd. Glaxosmithkline Pharmaceuticals Ltd. Indoco Remedies Ltd. Pan Drugs Ltd. Piramal Enterprises Ltd. Sanofi India Ltd. Sri Krishna Pharmaceuticals Ltd. Teva Pharmaceutical & Chemical Inds. India Pvt. Ltd. Triton Laboratories Ltd. For More Details, Click Here: - https://bit.ly/32McBPb Tags:- #Activepharmaingredients #pharmaingredients #IndianPharma #medicineingredients #paracetamolingredients #amoxicillinTrihydrate #Azithromycin #COVID19 #Paracetamol #coronavirus #CoronavirusBusiness #COVID2019 #CaronaBUSINESS #lockdownbusiness #businessinlockdown #coronavirusbusiness #Entrepreneurs #covid19business #DetailedProjectReport #businessconsultant #BusinessPlan #feasibilityReport #NPCS #industrialproject #entrepreneurindia #startupbusiness #startupbusinessideas #businessestostart #startupideas #startupbusinesswithnomoney #businessstartupindia #API
Plant capacity: -Plant & machinery: -
Working capital: -T.C.I: -
Return: 1.00%Break even: N/A
Add to Inquiry Add to Inquiry Basket

Disposable Surgical Mask Production. Investment and Business Opportunities in Medical Disposable Industry.

Disposable Surgical Mask Production. Investment and Business Opportunities in Medical Disposable Industry. Face masks are one tool utilized for preventing the spread of disease. They’ll even be called dental, isolation, laser, medical, procedure, or surgical masks. Face masks are loose-fitting masks that cover the nose and mouth, and have ear loops or ties or bands at the rear of the top. There are many various brands and that they are available different colors. It’s important to use a mask approved by the FDA. Related Projects:- Disposable Surgical Masks A surgical mask, also referred to as a face mask, is meant to be worn by health professionals during healthcare procedures. It’s designed to stop infections in patients and treating personnel by catching bacteria shed in liquid droplets and aerosols from the wearer's mouth and nose. They’re not designed to guard the wearer from breathing in airborne bacteria or viruses whose particles are smaller. With reference to some infections like influenza they seem as effective as respirators, such as N95 or FFP masks though the latter provide better protection in laboratory experiments because of their material, shape and tight seal. Related Books:- Disposable Products (Medical, Surgical, Thermocol, Plastic, Paper, Domestic And General Products) - Use And Throw Items, Single Use Items, Disposable Take-Away Packaging, Disposable Items Manufacturing Uses Disposable face masks are medical supplies that are worn to cover the mouth and nose and prevent people from inhaling poisonous airborne substances or other impure substances. Alternatively, it also is a shield against ill people that may unintentionally spread illnesses via the contaminants which may begin of their mouth. Generally, in medical health care centre, disposable face masks are wont to prevent the spread of infections from patients who are sick. The masks are quite effective when the patient comes in touch with people. However, facemasks also are worn by the hospital staff and employees working in medical healthcare institutions because they frequently affect different sorts of patients having varied varieties of diseases. Research Report: - Market Research Report Disposable face masks are known by different names. A number of these terms are surgery masks, medical procedure masks, and laser and isolation masks. Face masks are available in different shapes and sizes alongside varied densities of thickness. The thickness of the mask significantly affects the breathing capabilities of the person wearing it. If the thickness of the mask is high, then it'll make the breathing difficult. Which is why, at times, people with affected by asthma and emphysema may need to consult a doctor before wearing face masks. Related Videos: - Manufacturing of Medical Disposable Face Masks. How are Surgical Masks Made? Surgical face masks are made with non-woven fabric, which has better bacteria filtration and air permeability while remaining less slippery than woven cloth. The material most commonly used to make them is polypropylene, either 20 or 25 grams per square meter (gsm) in density. Masks can also be made of polystyrene, polycarbonate, polyethylene, or polyester. Project Identification 20 gsm mask material is made in a spun bond process, which involves extruding the melted plastic onto a conveyor. The material is extruded in a web, in which strands bond with each other as they cool. 25 gsm fabric is made through melt blown technology, which is a similar process where plastic is extruded through a die with hundreds of small nozzles and blown by hot air to become tiny fibers, again cooling and binding on a conveyor. These fibers are less than a micron in diameter. Related Projects:- Surgical, Medical Plastics, Medical Disposables, Disposable Medical Products used in Hospitals Surgical masks are made up of a multi-layered structure, generally by covering a layer of textile with non-woven bonded fabric on both sides. Non-woven, which are cheaper to make and cleaner thanks to their disposable nature, are made with three or four layers. These disposable masks are often made with two filter layers effective at filtering out particles such as bacteria above 1 micron. The filtration level of a mask, however, depends on the fiber, the way it’s manufactured, the web’s structure, and the fiber’s cross-sectional shape. Masks are made on a machine line that assembles the nonwovens from bobbins, ultrasonically welds the layers together, and stamps the masks with nose strips, ear loops, and other pieces. Completed masks are then sterilized before being sent out of the factory. Related Books: - Handbook on Medical and Surgical Disposable Products Market Outlook Indian market Surgical masks are disposable devices that cover the mouth and nose during medical procedures. They prevent the spread of infection between diseased and healthy population. Surgical masks are typically used in a health facility (hospitals, emergency departments, out-patient facilities, residential care facilities, emergency medical services) and home health care delivery. The India surgical mask market was valued at $71.73 million in 2019, and is expected to reach $157.13 million by 2027, registering a CAGR of 10.3% from 2020 to 2027. Related Video: - Production of Disposable Surgical and Medical Face Mask However, surgical disposables like masks, contain absorbent chemicals and are discarded after use. Most of those masks are made from superabsorbent polymers like polyacrylate, which are non-biodegradable. These products contain quite 90% plastic with superabsorbent polymers and non-woven plastic components. Thus, the disposal issue of those masks has become an environmental hazard, which impedes the growth of the India surgical masks market. Similarly, increase in usage of less invasive surgeries is anticipated to decrease the utilization of surgical masks within the upcoming years. Minimally invasive surgeries are estimated to scale back the usage of surgical apparels like surgical masks, caps, and others in hospitals, during operative procedures. Additionally, the utilization of efficient robotics in surgical procedures is further anticipated to scale back the demand for protective apparels required by surgeons during medical procedures. Conversely, technological integration within the process of surgical masks making is predicted to make beneficial opportunities within the future. Advancements in production of reusable nonwoven products like antimicrobial fibers and improved comfort are expected to fuel the expansion of the India surgical masks market. Related Projects:- Disposable Products and Projects from Paper, Plastic, Thermocol, Banana Leaves (Use and Throw Items, Throwing Item, Single Use Items, Disposable Take-Away Packaging, Disposable Food Packaging, Disposable Items Manufacturing) Conversely, increase in concerns regarding the disposal of surgical masks and rise in popularity of lesser invasive surgeries are foreseen to impede the market growth in coming years. On the contrary, innovations in nanotechnology and its increased use in surgical mask production together with upsurge in demand for single use of nonwoven surgical mask are predicted to make remunerative opportunities for the India surgical masks market growth within the near future. Related Project Blog: - Blog Global Market Increasing need for improved safety standard has led to the rise within the growth of the surgical mask market as success rate of surgeries largely depends on the extent of safety and precautions taken during surgeries. Surgical mask are used as a barrier to avoid cross contamination by microorganisms and are used during surgical procedures. The surgical mask is used by surgeons during procedures and other medical professionals while interacting with the patients to avoid cross contamination of microorganisms. The patient who is under treatment also must be protected against infectious agents that's set to be discharged by others within the surgery rooms. Related Projects: - Healthcare and Medical Businesses The demand within the worldwide marketplace for surgical mask has been rising on account of advancements within the field of medical surgery and diagnosis. Surgical masks are meant to guard doctors and surgeons from harmful infections and pathogens which will get suspended within the surgery room. Furthermore, the patient who is under treatment also must be shielded from infectious agents which will be discharged by others within the surgery rooms. Hence, the worldwide marketplace for surgical mask is predicted to expand at a stellar pace within the years to follow. There are multiple attempts at manufacturing improved surgical masks, and this has given an impetus to plug growth. Projects:- Project Reports & Profiles The Global Disposable Face Masks Market size is expected to reach $91.3 billion by the end of 2020, rising at a market growth of 97.4% CAGR during the forecast period (2019-2025). Disposable face masks are widely prevalent among medical professionals, industry workers, sanitation personnel, laboratory workers, police and security personnel, airport security personnel, and the general public. These masks are practically worn by anyone who opts to add an extra safety precaution of hygiene and safety in their daily routine. The global disposable face masks market includes the type of face masks that are used for covering the nose and the mouth of the wearer for providing protection against contamination, infection, protection from potential viruses as well as foreign or harmful elements in the surrounding. Books:- BOOKS & DATABASES Key Players Key players operating in the India surgical masks market such as Thea-Tex Healthcare (India) Pvt. Ltd., Venus Safety & Health Pvt. Ltd., Magnum Health and Safety Private Limited, Z Plus Disposable, Salus Products, Smilepad Hygiene India Pvt. Ltd., Cartel Healthcare Pvt. Ltd., MBL Impex Private Limited, Medicare Hygiene Limited, Mediblue Health Care Private Limited., Plasti Surge Industries Pvt. Ltd., Medline Industries Inc., Premium Health Care Disposables Private Limited, Kwalitex Healthcare Private Limited, and 3M Company Tags:- #disposablesurgicalmasks #facemask #mask #surgicalmasks #SurgicalMaskProduction #Covid19Pandemic #SurgicalMaskMarket #medicalmasks #protectionmask #SafeFaceMask #disposablemask #cottonmasks #N95Mask #KN95Mask #COVID_19 #MedicalFaceMask #MedicalMask #3PlyFaceMask #3PlyMask #3LayerFaceMask #3LayerMask #COVID19 #DetailedProjectReport #businessconsultant #feasibilityReport #NPCS #BusinessPlan #startupideas #entrepreneurindia #startupbusiness #projectreport #DetailedProjectReport #businessconsultant #BusinessPlan #feasibilityReport #NPCS
Plant capacity: -Plant & machinery: -
Working capital: -T.C.I: -
Return: 1.00%Break even: N/A
Add to Inquiry Add to Inquiry Basket

Best Business Opportunity to Start Dairy Farming & Dairy Products, Groundnut Oil, Nicotine from Tobacco Waste, IV Fluids (BFS Technology), Disposable Nitrile Gloves, Toothpaste, Active Pharma Ingredients (API),

Best Business Opportunity to Start Dairy Farming & Dairy Products, Groundnut Oil, Nicotine from Tobacco Waste, IV Fluids (BFS Technology), Disposable Nitrile Gloves, Toothpaste, Active Pharma Ingredients (API), Are you searching for manufacturing business ideas? If you have sizeable money to invest and a more risk-taking ability, starting a business is a good decision. Product manufacturers can generate new value, minimize costs, and increase operational stability by focusing and prioritizing on four broad areas: production, product design, value recovery, and supply-chain management. Thinking about stepping into manufacturing industry business, you need to consider the option of starting on a limited size production. Starting with the making of essential components of the various industries. Once you set up things well, you could choose to start an industry and gradually become the giant of the industry. Projects:- Project Reports & Profiles Get ready and quickly go through these top business ideas that are the best options available with high return on investment. Choose any of these high net profit margin ideas if you want to start a venture in the manufacturing industry. Becoming an entrepreneur easier than ever before—technology is shrinking the world, opening markets, and making it possible for many people to strike out on their own in the field of their dreams. An entrepreneur who starts his own business can break free from this actuarial perspective and redefine the value he brings to the market. Books:- BOOKS & DATABASES Dairy Farming & Dairy Products (Milk, Butter, Ghee & Paneer) Dairy farming may be a class of agriculture for long-term production of milk, which is processed for eventual sale of a dairy product. Dairying is a very important source of subsidiary income to small/marginal farmers and agricultural laborers. India derives nearly 33% of the gross Domestic population from agriculture and has 66% of economically active population, engaged in agriculture. The share of livestock product is estimated at 21% of total agriculture sector. Milk production alone involves over 70 million producers, each raising one or two cows/buffaloes primarily for milk production. Additionally to exploit, the manure from animals provides an honest source of organic matter for improving soil fertility and crop yields. The gobar gas from the dung is used as fuel for domestic purposes as also for running engines for drawing water from well. In Hinduism; cow urine features a special significance as a drink. Sprinkling of cow urine is said to possess a spiritual cleansing effect furthermore. Gomutra isn't a toxic industrial waste material. 95% of its water, 2.5% consists of urea, and therefore the remaining 2.5% may be a mixture of minerals, salts, hormones and enzymes. Related Projects:- Milk & Dairy Products The global dairy products market is expected to grow at a CAGR of 5.2% from 2019 to reach $645.8 billion by 2025. Dairy is defined as a business enterprise that deals with the processing and harvesting of animal milk for human consumption. Some of the common milch animals include cow, goat, buffalo, camel and sheep. The milk obtained from these animals can be consumed directly and processed into ice cream, cheese, paneer, butter, ghee, condensed milk and yogurt. These products offer various nutrients such as calcium, proteins, zinc, magnesium, and vitamin D and B12. With widespread demand for dairy products and their proactive function in the global food industry, dairy plays a crucial role in the growth of the economies worldwide. Over the years, the dairy industry has witnessed improvements in product safety through specialization, modernization and consolidation. Moreover, advancements in global trade have also influenced the profitability of dairy farms. Related Books:- Milk Processing, Dairy & Dairy Products, Poultry Industries As of 2018, India is the leading milk producing country in the world, accounting for ~19% of the global market share. The milk processing industry in India is expected to expand at a compound annual growth rate (CAGR) of ~14.8% between FY 2018 and FY 2023, and will reach INR 2,458.7 Bn in FY 2023. Groundnut Oil Groundnut oil may be a vegetable oil derived from groundnuts. It’s also called groundnut oil. The oil features a strong peanut flavor and aroma. It’s often utilized in American, Chinese, South Asian and Southeast Asian cuisine, both for general cooking, and within the case of roasted oil, for added flavor. Unrefined groundnut oil features a smoke point of 320°F/160°C and is employed as a flavor ant for dishes like sesame oil. Groundnut haulms are nutritious and widely used for feeding livestock. The groundnut oil consists of mixed glycerides, and contain a high proportion of unsaturated fatty acids, especially Oleic (50-56%) and Linoleic (18-30%). Related Projects: - Edible Oils Projects In India, groundnut is cultivated in 5.8 million hectares. Gujarat is that the highest producer of groundnut oil in India. Groundnut seed contains 50-55% of the oil. It’s one among the most effective oil seeds to extract oil from. Increasing use of groundnut oil in cosmetics are getting to be one altogether the primary drivers of the peanut oil market. The abrasive, volatizing, and cleansing properties of hot-pressed groundnut oil and its derivatives are boosting its application in BPC product and cosmetics, such as moisturizers and skin cleansers. Growing popularity of blended oil are getting to be one altogether the critical groundnut oil market trends. The utilization of cheap alternatives, similar to oil in blended oil makes it more affordable than conventional oil. These advantages can boost the popularity of homogenized groundnut oil and consequently fuel the growth of the groundnut oil market. Related Books:- Market Research Report on Edible Oils in India However, the high production cost of peanut oil is a major factor expected to restraint growth of the target market in the near future. In addition, high consumption of peanut oil results in various side effects in human health which is one of the major factors expected to hamper growth of the target market to a certain extent. Global peanut oil market is set to witness a steady CAGR of 4.25% in the forecast period of 2019- 2026. Nicotine from Tobacco Waste Nicotine may be a natural product of tobacco, occurring within the leaves of nicotiana tabacum during a range of 0.5 to 7.5% counting on variety. Nicotine is additionally found within the leaves of nicotiana rustica, in amounts of 2–14%; in Duboisia hopwoodii and in Asclepias syriaca. Nicotine may be a widely used stimulant and potent par sympathomimetic alkaloid that's naturally produced within the nightshade family of plants. It’s used for smoking cessation to alleviate withdrawal symptoms. Nicotine may be a widely used stimulant and potent para sympathomimetic alkaloid that's naturally produced within the nightshade family of plants. It’s used for smoking cessation to relieve withdrawal symptoms. Related Projects:- Tobacco, Pan Masala, Khaini, Gutkha, Supari, Zarda, Mouth Freshener The India Tobacco Board has authorized a 2020 Traditional FCV crop size of 90 million kilos. However, crop size is estimated at 96 million kilos. A grade spread consisting of 20 million kilos of bright, 25 million kilos of the medium, and 51 million kilos of low style tobacco. 90% of the crop is already harvested. The average market price is USD 2.10 for this year. Indian Tobacco Board has authorized an NLS 2020 crop size of 46 million kilos. However, a crop size 42 million kgs is anticipated which was transplanted in 17,000 hectares and 90% of the crop has been harvested. The average market price is expected to be USD 2.30 for this year. Related Books:- Agriculture, Agro Based, Bakery, Wood, Ice Cream, Corn, Tobacco And Tobacco Products IV Fluids (BFS Technology) Intravenous fluids are fluids which are intended to be administered to a patient intravenously, directly through the circulatory system. These fluids must be sterile to guard patients from injury, and there are variety of various types available to be used. Many companies manufacture packaged intravenous fluids, also as products which may be mixed with sterile water to prepare a solution for intravenous administration. Fluids are given when someone's body fluid volume falls. There are variety of things which may cause a drop by fluid volume. Vomiting and diarrhea are a classic example, which is why people are encouraged to drink fluids once they are sick, to stay their fluid volume stable. Another cause is blood loss, which causes problems both because people lose blood products, and because they experience a loss in fluid volume. Electrolyte levels within the blood also can become unstable as a result of rapid changes in fluid volume, during which case intravenous fluids are often used to restore the balance. Related Projects:- IV Fluids, I.V. solutions, Intravenous fluids The primary costumers for these manufacturing units are Hospitals, Clinics, Dialysis centers, Home care settings. The global Intravenous Fluid market size was valued at US$ 8,372.0 million in 2019 and is expected to witness a CAGR of 6.1% over the forecast period (2019 – 2027). The basic function of I.V. fluids is to replenish body fluids. It can also be used in the treatment of electrolyte metabolism, especially in severe cases, therapy of acid-base in balances, the volume substitution and volume replacement in surgery of accident victims suffering blood loss. It can be used as parenteral nutrition for severally ill and post-operative patients. Related Books:- BOOKS & DATABASES Disposable Nitrile Gloves Nitrile gloves are a kind of disposable gloves made up of synthetic rubber, this suggests there's no risk of latex allergies. They the foremost popular gloves type in our range and offer superior strength, dexterity and resistance to oils and aqueous chemicals as compared to vinyl or latex. For these reasons, they're often utilized in the medical, laboratory and manufacturing industries. Nitrile gloves are an excellent compromise between latex and vinyl. Our Blue Nitrile gloves offer protection from bodily fluids providing a barrier that forestalls infection, cross-infection or cross-contamination. Tests revealed that Nitrile gloves are three times more puncture-resistant than rubber gloves. Related Projects:- Disposable Products and Projects from Paper The Indian market for medical gloves is still evolving. While the global market is growing at a compound annual growth rate (CAGR) of two per cent, the Indian market is at seven per cent growth. Every day there is a new hospital or nursing home popping up in India, so the demand for medical gloves is expected to increase. Medical tourism is also driving the growth of this product category in our country. The market size therefore only for gloves in India is Rs 300 crore. In view of all this, there is a good scope to initiate small-scale rubber gloves manufacturing unit. The Global Rubber Gloves market is expected to grow at a CAGR of 8.5% between 2014 and 2022. The factors such as rising healthcare expenditure, increasing health threats and increasing hygiene awareness and healthcare regulations are driving the market growth. Related Video:- Production of Disposable Nitrile Gloves Nitrile gloves are preferred over latex gloves because they resist chemicals, including certain disinfectants such as chlorine. There is a high rate of allergies to latex and contact allergic dermatitis among health workers. Non powdered gloves are preferred to powdered gloves. Toothpaste Toothpaste may be a paste or gel to be used with a toothbrush to maintain and improve oral health and aesthetics. Since their introduction several thousand years ago, toothpaste formulations have evolved considerably - from suspensions of crushed egg shells or ashes to complex formulations with often over 20 ingredients. Among these are often compounds to combat dental caries, gum disease, malodor, calculus, erosion and dentin hypersensitivity. Furthermore, toothpastes contain abrasives to wash and whiten teeth, flavors for the aim of breathe freshening and dyes for better visual appeal. Effective toothpastes are people who are formulated for maximum bioavailability of their actives. This, however, are often challenging as compromises will need to be made when several different actives are formulated in one phase. Related Projects:- Hygiene Products, Essential Personal Hygiene Products The global toothpaste market is projected to grow at a CAGR of 6.1% during the forecast period. The toothpaste market was valued at USD 26.09 billion in 2018, and it is projected to reach USD 36.98 billion by 2024. Increasing dental problems among children and adults, due to poor eating habits, and the rise in popularity for herbal oral care products are the factors primarily driving the global toothpaste market. Related Video:- Startup Business Opportunities in Toothpaste The rapidly changing lifestyle, improper diet, including sugar-rich diets, and therefore the increased consumption of alcohol and tobacco have made oral health one among the main public health problems in almost every a part of the planet. The impact of oral diseases on people's everyday lives is subtle and pervasive, influencing food habits, sleep, rest, social roles, and almost every phase of the day. Collectively, oral diseases and disorders create substantial pain and suffering. Because of this, consumers across the planet have started paying immense attention to maintaining their oral health, which has led to a rise within the sales of toothpaste across the world. Active Pharma Ingredients (API) (Cephalexin, Ampicillin Trihydrate, Ibuprofen and Paracetamol) The Active Pharmaceutical Ingredient (API) is that the part of any drug that produces the intended effects. Some drugs, like combination therapies, have multiple active ingredients to treat different symptoms or act in several ways. Production of APIs has traditionally been done by the pharmaceutical companies themselves in their home countries. But in recent years many corporations have opted to send manufacturing overseas to chop costs. This has caused significant changes to how these drugs are regulated, with more rigorous guidelines and inspections put into place. Related Projects:- Active Pharmaceutical Ingredient (API) Products, Bulk API Manufacturing India is that the seventh largest country within the world and has the second highest population. It a parliamentary democratic variety of government and has abundant natural resources and sufficient oil reserves. The country features a huge skilled, English-speaking, and inexpensive labor force. Its young population and current economic policies have made it one among the most important recipients of FDI within the world. Asia Pacific is predicted to be the fastest-growing market over the forecast period. Because of the supply of affordable labor, major companies within the market are setting up API manufacturing plants in developing countries like China and India. The global demand of APIs include ageing population, rising expenditures on healthcare, increasing prevalence of lifestyle diseases, etc. Looking forward, the market value is projected to reach US$ 258.8 Billion by 2025, exhibiting a CAGR of 5.6% during 2020-2025. The API market is competitive in nature and is becoming increasingly competitive. Consequently, manufacturers are required to enhance products in order to gain advantage over previously marketed products. Related Book:- India Active Pharmaceutical Ingredient (API) Market The government also notified a scheme to promote bulk drug parks. For selected parks, financial assistance to the tune of 70 per cent of the project cost of common infrastructure facilities will be provided. In the case of Northeast states and hilly states (Himachal Pradesh, Uttarakhand, Union Territory of Jammu & Kashmir, and Union Territory of Ladakh), financial assistance will be 90 per cent of the project cost. The maximum assistance under the scheme for one bulk Drug Park will be limited to Rs 1,000 crore. The total financial outlay of the scheme is Rs 3,000 crore. Tags:- #dairy #dairyfarming #DairyProducts #dairyindustry #GroundnutOil #Nicotine #tobaccowaste #IVFLUIDS #disposablenitrilegloves #disposablegloves #toothpaste #toothpastebusiness #hygieneindustry #ToothpasteIndustry #ToothpasteMarket #ToothpasteProject #activepharmaingredients #API #apimanufacturing #Apiproduction #ActivePharmaceuticalIngredient #pharmaceuticalindustry #apimarket #businessconsultant #businessfeasibilityreport #DetailedProjectReport #EntrepreneurIndia #startupideas #NPCS
Plant capacity: -Plant & machinery: -
Working capital: -T.C.I: -
Return: 1.00%Break even: N/A
Add to Inquiry Add to Inquiry Basket

E-Waste Recycling Plant

Electronic wastes, "e-waste", "e-scrap", or "Waste Electrical and Electronic Equipment" ("WEEE") is a description of surplus, obsolete, broken or discarded electrical or electronic devices. Technically, electronic "waste" is the component which is dumped or disposed or discarded rather than recycled, including residue from reuse and recycling operations. Because loads of surplus electronics are frequently coming led (good, recyclable, and non-recyclable), several public policy advocates apply the term "e-waste" broadly to all surplus electronics. Electronic Waste – or e-waste – is the term used to describe old, end-of-life electronic appliances such as computers, laptops, TVs, DVD players, mobile phones, mp3 players etc. which have been disposed of by their original users. While there is no generally accepted definition of e-waste, in most cases, e-waste comprises of relatively expensive and essentially durable products used for data processing, telecommunications or entertainment in private households and businesses. The rising levels of e-waste generation in India have been a matter of concern in recent years. With more than 100 crore mobile phones in circulation, nearly 25 per cent end up in e-waste annually. “India has surely emerged as the second largest mobile market with 1.03 billion subscribers, but also the fifth largest producer of e-waste in the world, discarding roughly 18.5 lakh metric tonnes of electronic waste each year, with telecom equipment alone accounting for 12 per cent of the e-waste’’. The fastest growing sources of waste and is estimated to be increasing by 16-28 per cent every five years. Within each sector a complex set of heterogeneous secondary wastes is created. Although treatment requirements are complicated, the sources from any one sector possess many common characteristics. However, there exist huge variations in the nature of electronic wastes between sectors, and treatment regimes appropriate for one cannot be readily transferred to another. The ‘Electronic Waste Management in India,’ conducted to mark World Environment Day, said as Indians become richer and spend more on electronic items and appliances, computer equipment accounts for almost 70% of e-waste material, followed by telecommunication equipment (12%), electrical equipment (8%) and medical equipment (7%). Other equipment, including household e-crap account for the remaining 4%. India is emerging as one of the world's major electronic waste generators, posing grave concerns to public health and environment alike. Industry body Assocham, said India’s ‘production’ of e-waste is likely to increase by nearly three times, from the existing 18 lakh metric tons (MT) to 52 lakh MT) per annum by 2020 at a compound annual growth rate (CAGR) of about 30%.The Global Electronic Waste Recycling Market is expected to expand at 13.03% CAGR to reach a market value of 39,498.81 Million in 2024. A mere 1.5% of India's total e-waste gets recycled due to poor infrastructure, legislation and framework which leads to a waste of diminishing natural resources, irreparable damage of environment and health of the people working in industry. Over 95% of e-waste generated is managed by the unorganized sector and scrap dealers in this market, dismantle the disposed products instead of recycling it. The market in Asia-Pacific has been categorized as China, Japan, India, and the rest of Asia-Pacific. The market in Asia-Pacific is expected to register the highest CAGR of 15.25% during the forecast period. Japan is expected to be a leading country-level market and is expected to register a 12.75% CAGR. India is expected to be the fastest-growing country-level market, expected to register the highest CAGR over the next few years. This is due to the growing population in the region. Also, growing awareness of e-waste recycling and government initiatives are the major factors for the growth of the market.
Plant capacity: Plastic Granules: 470 Kgs / Day Glass Scrap: 353 Kgs / Day Copper Scrap: 294 Kgs / Day Precious Metals (Nickel, Tin & Zinc): 60.00 Kgs / Day Gold : 0.0192 Kgs / Day Silver: 0.0384 Kgs / Day Palladium: 0.0010 Kgs / DaPlant & machinery: Rs 107 lakhs
Working capital: -T.C.I: Cost of Project : Rs 336 lakhs
Return: 28.00%Break even: 58.00%
Add to Inquiry Add to Inquiry Basket

Active Pharma Ingredients • Azithromycin • Cefixime • Telmisartan • Diclofenac sodium • Acecloflenac

Active pharmaceutical ingredients are the active substances that are used in the manufacture of a drug and have a pharmacological effect. They provide health benefits and play a vital role in disease diagnosis, prevention, and treatment. Active pharmaceutical ingredients may be synthesized either chemically or through biotechnological methods. The Active Pharmaceutical Ingredient (API) is the part of any drug that produces the intended effects. Some drugs, such as combination therapies, have multiple active ingredients to treat different symptoms or act in different ways. Active pharmaceutical ingredient (API), is the term used to refer to the biologically active component of a drug product (e.g. tablet, capsule). Drug products are usually composed of several components. The aforementioned API is the primary ingredient. Other ingredients are commonly known as "excipients" and these substances are always required to be biologically safe, often making up a variable fraction of the drug product. The procedure for optimizing and compositing this mixture of components used in the drug is known as "formulation." The global active pharmaceutical ingredient market size is expected to reach a value of USD 286.6 billion by 2027, registering a CAGR of 6.7% over the forecast period. Factors, such as increasing preference for outsourcing APIs and growing prevalence of various target diseases such as cancer and Cardiovascular Diseases (CVDs) are expected to drive the market growth. The Asia Pacific is expected to emerge as the fastest-growing regional market due to rapidly increasing the prevalence of therapeutic and chronic diseases i.e., diabetes, cancer etc. with rising population in this region. According to WHO, around 65% of all cancer deaths occur in developing countries and the number of global cancer deaths is projected to increase by 45 percent from 2007 to 2030 with from 7.9 million to 11.5 million deaths influenced by rise in consumption of tobacco use, unhealthy diet, insufficient physical activity and the harmful use of alcohol in this region. The active pharmaceutical ingredients market gets a major boost from the growing prevalence of cardiovascular conditions, infectious diseases, and various other chronic disorders. Other than these, the rise in various genetic disorders has driven the use of biologicals and biosimilars, the world over. In many instances, biosimilars are the most preferred owing to them being low-cost. Biosimilars have the potential of creating a highly sustainable healthcare system which makes way for innovation, allowing more patients to receive the optimum care. Thus, due to demand it is best to invest in this project. Few Indian major players are as under Alpha Remedies Ltd. Ankur Drugs & Pharma Ltd. Aurobindo Pharma Ltd. Farmson Pharmaceutical Gujarat Pvt. Ltd. Glaxosmithkline Pharmaceuticals Ltd. Sanofi India Ltd. Piramal Enterprises Ltd. Teva Pharmaceutical & Chemical Inds. India Pvt. Ltd.
Plant capacity: Azithromycin: 500 Kgs / Day Cefixime: 500 Kgs / Day Telmisartan: 50 Kgs / Day Diclofenac Sodium: 500 Kgs / Day Aceclofenac: 500 Kgs / DayPlant & machinery: Rs 155 lakhs
Working capital: -T.C.I: Cost of Project : Rs 729 lakhs
Return: 31.00%Break even: 61.00%
Add to Inquiry Add to Inquiry Basket

Active Pharma Ingredients • Azithromycin • Cefixime • Telmisartan • Diclofenac sodium • Acecloflenac

Active pharmaceutical ingredients are the active substances that are used in the manufacture of a drug and have a pharmacological effect. They provide health benefits and play a vital role in disease diagnosis, prevention, and treatment. Active pharmaceutical ingredients may be synthesized either chemically or through biotechnological methods. The Active Pharmaceutical Ingredient (API) is the part of any drug that produces the intended effects. Some drugs, such as combination therapies, have multiple active ingredients to treat different symptoms or act in different ways. Active pharmaceutical ingredient (API), is the term used to refer to the biologically active component of a drug product (e.g. tablet, capsule). Drug products are usually composed of several components. The aforementioned API is the primary ingredient. Other ingredients are commonly known as "excipients" and these substances are always required to be biologically safe, often making up a variable fraction of the drug product. The procedure for optimizing and compositing this mixture of components used in the drug is known as "formulation." The global active pharmaceutical ingredient market size is expected to reach a value of USD 286.6 billion by 2027, registering a CAGR of 6.7% over the forecast period. Factors, such as increasing preference for outsourcing APIs and growing prevalence of various target diseases such as cancer and Cardiovascular Diseases (CVDs) are expected to drive the market growth. The Asia Pacific is expected to emerge as the fastest-growing regional market due to rapidly increasing the prevalence of therapeutic and chronic diseases i.e., diabetes, cancer etc. with rising population in this region. According to WHO, around 65% of all cancer deaths occur in developing countries and the number of global cancer deaths is projected to increase by 45 percent from 2007 to 2030 with from 7.9 million to 11.5 million deaths influenced by rise in consumption of tobacco use, unhealthy diet, insufficient physical activity and the harmful use of alcohol in this region. The active pharmaceutical ingredients market gets a major boost from the growing prevalence of cardiovascular conditions, infectious diseases, and various other chronic disorders. Other than these, the rise in various genetic disorders has driven the use of biologicals and biosimilars, the world over. In many instances, biosimilars are the most preferred owing to them being low-cost. Biosimilars have the potential of creating a highly sustainable healthcare system which makes way for innovation, allowing more patients to receive the optimum care. Thus, due to demand it is best to invest in this project. Few Indian major players are as under Alpha Remedies Ltd. Ankur Drugs & Pharma Ltd. Aurobindo Pharma Ltd. Farmson Pharmaceutical Gujarat Pvt. Ltd. Glaxosmithkline Pharmaceuticals Ltd. Sanofi India Ltd. Piramal Enterprises Ltd. Teva Pharmaceutical & Chemical Inds. India Pvt. Ltd.
Plant capacity: Azithromycin: 500 Kgs / Day Cefixime: 500 Kgs / Day Telmisartan: 50 Kgs / Day Diclofenac Sodium: 500 Kgs / Day Aceclofenac: 500 Kgs / DayPlant & machinery: Rs 155 lakhs
Working capital: -T.C.I: Cost of Project : Rs 729 lakhs
Return: 31.00%Break even: 61.00%
Add to Inquiry Add to Inquiry Basket

Lithium Ion Battery (Battery Assembly)

Lithium batteries are now powering a wide range of electrical and electronically devices, including laptop computers, mobile phones, power tools, telecommunication systems and new generations of electric cars and vehicles. Lithium metal batteries and lithium ion batteries. Basically, the difference between them is that lithium metal batteries are those that are not rechargeable, thus, primary, and lithium ion batteries are those that can be recharged. As an example, your laptop or cell phone is likely to have a lithium ion battery, whereas your watch may have a lithium metal battery. The India lithium-ion battery market is expected to grow at a robust CAGR of 29.26% during the forecast period, 2018-2023. The Indian automobile sector is one of the most prominent sectors of the country, accounting for nearly 7.1% of the national GDP. The industry produced a total of 25.31 million vehicles, including commercial, passenger, two, and three vehicles and commercial quadricycle in April-March 2017, as against 24.01 million in April-March 2016. However, India has set itself an ambitious target of having only electric vehicles (EV) by 2030, which is expected to increase the demand for lithium-ion batteries in India, significantly. “In the coming years, India is expected to witness substantial investments by various companies to set up their Li-ion battery manufacturing base in the country. Entrepreneurs who invest in this project will be successful. Few Indian major players are as under H B L Power Systems Ltd. Luminous Power Technologies Pvt. Ltd. Okaya Power Pvt. Ltd. Eon Electric Ltd. Carborundum Universal Ltd. Bharat Electronics Ltd.
Plant capacity: 48 Volt, 60 AH Lithium-Ion Battery Pack : 5 Nos / Day 48 Volt, 80 AH Lithium-Ion Battery Pack : 5 Nos / Day 48 Volt, 100 AH Lithium-Ion Battery Pack : 5 Nos / Day 60 Volt, 20 AH Lithium-Ion Battery Pack : 5 Nos / Day 60 Volt, 30 AH Lithium-Ion Battery PacPlant & machinery: Rs 306 lakhs
Working capital: -T.C.I: Cost of Project : Rs 648 lakhs
Return: 28.00%Break even: 62.00%
Add to Inquiry Add to Inquiry Basket

Azithromycin, Cefixime, Telmisartan, Diclofenac Sodium, Acecloflenac Manufacturing. Production of Active Pharma Ingredients (API).

Azithromycin, Cefixime, Telmisartan, Diclofenac Sodium, Acecloflenac Manufacturing. Production of Active Pharma Ingredients (API). Opportunities for Entrepreneurs to Start Own Industry. The active pharmaceutical ingredient (API) is the part of any drug that produces the intended effects. Some drugs, such as combination therapies, have multiple active ingredients to treat different symptoms or act in different ways. Active pharmaceutical ingredients are the active substances that are used in the manufacture of a drug and have a pharmacological effect. They provide health benefits and play a vital role in disease diagnosis, prevention, and treatment. Active pharmaceutical ingredients may be synthesized either chemically or through biotechnological methods. Related Project: - Active Pharma Ingredients • Azithromycin • Cefixime • Telmisartan • Diclofenac Sodium • Acecloflenac Active Pharmaceutical Ingredient (API) is the portion of drug that generates intentional effects. APIs are biologically and chemically active constituents of medicines with direct effect in mitigation, prevention, cure and treatment of diseases. Some of the medicines like combination therapies have many active ingredients to treat diverse symptoms or perform in numerous ways. Active Pharmaceutical Ingredient has active ingredient that is contained in medicine. For illustration, an active ingredient to reduce pain is incorporated in a painkiller. A slight amount of the active ingredient has result thus only small part of the active ingredient is confined in medicine. Role of Government towards API The coronavirus outbreak disrupting supply of active pharmaceutical ingredients (APIs) and medical devices from China to India, the government has come out with four schemes worth Rs 13,760 crore to encourage manufacturing of bulk drugs and medical devices in the country and their exports. On March 21, the Union Cabinet under the chairmanship of Prime Minister Narendra Modi had approved an expenditure of Rs. 9,940 crore and Rs. 3,820 crore for APIs and medical devices, respectively. Related Videos: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Pharmaceutical Drugs, Pharma Drug Ingredients Intermediates, Pharmaceutical Bulk Drugs The Cabinet also approved a scheme on promotion of bulk drug parks for financing common infrastructure facilities in three bulk drug parks with financial implication of Rs. 3,000 crore for next five years. The government will give grants-in-aid to states with a maximum limit of Rs. 1,000 crore per bulk Drug Park. Parks will have common facilities such as solvent recovery plant, distillation plant, power and steam units, common effluent treatment plant etc. The government further approved production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/drug intermediates and APIs in the country with financial implications of Rs. 6,940 crore for next eight years. Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. Rate of incentive will be 20 per cent (of incremental sales value) for fermentation based bulk drugs and 10 per cent for chemical synthesis based bulk drugs. The PLI scheme will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over eight years. The drug industry has welcomed the incentives offered by the government to promote API units in India. Besides APIs, the Cabinet also approved the scheme for promotion of medical device parks in the country in partnership with the states. A maximum grant-in-aid of Rs. 100 crore per park will be provided to the states. It will have financial implications of Rs. 400 crore. The PLI scheme for promoting domestic manufacturing of medical devices will have financial implications of Rs. 3,420 crore for next five years. Medical device is a growing sector and its potential for growth is the highest among all sectors in the healthcare market. It is valued at Rs. 50,026 crore for 2018-19 and is expected to reach to Rs. 86,840 crore by 2021-22. India depends on imports up to an extent of 85 per cent of total domestic demand of medical devices. Union Cabinet scheme on Promotion of Bulk Drug Parks • The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years. • Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6,940 crore for next eight years. Details: Promotion of Bulk Drug Parks • Decision is to develop 3 mega Bulk Drug parks in India in partnership with States. • Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park. • Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc. • A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years. Production Linked Incentive Scheme • Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. • Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. • Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs. • A sum of Rs. 6,940 crore has been approved for next 8 years. Market Outlook Active Pharmaceutical Ingredients Market Dynamics The growing cases of chronic diseases are one of the leading causes of hospitalization, and a majority of the patients with these conditions may need re-admission in hospitals due to infection leading to other chronic diseases. For instance, according to the report published by the Centers for Disease Control and Prevention (CDC), nearly 92.1 million adults in the US dealt with at least one type of cardiovascular disease in 2017. Besides, CDC has also stated that out of the total annual healthcare expenditure, i.e., USD 27 trillion, 86% is for the people with chronic health conditions in the US. Some of the prime factors spurring the growth of the market are increasing occurrences of cardiovascular, oncology, lifestyle and diabetes diseases, intensifying number of diagnostic centers and hospitals and escalating elderly population in emerging countries. Furthermore, cumulative healthcare spending, growing disease responsiveness and education are propelling the growth of the market. Related Projects: - Active Pharmaceutical Ingredient (API) Products, Bulk API Manufacturing With advancements in healthcare infrastructure, healthcare spending has increased over time. This augmenting focus on healthcare spending positively influences the market for active pharmaceutical ingredients. The high adoption rate of generic drugs in developed and developing economies is fueling the growth of the market. Another positive impact comes from the high demand for specialty medicines which is anticipated to escalate the spending in the pharmaceutical sector. Developed nations are expected to exhibit faster growth in these spending as compared to the developing economies on the back of factors such as the presence of adequate manufacturing units, transparent pricing, and higher spending power. Specialty medicines a trend in the active pharmaceutical ingredients market A higher generic adoption rate in developed countries that ranges from 27% to 32% is driving global medicine spending and aiding greater access to improved, lifesaving healthcare services. The adoption of branded generic drugs is predicted to be higher in emerging economies such as China and India and generic drugs accounted for nearly 80% of the total drugs sold by value in these fast-growing nations in 2016. Rising use of specialty medicines is anticipated to grow the pharmaceutical spending worldwide with quicker growth in richer, developed nations as compared to their emerging counterparts. This is primarily because the former have adequate manufacturing units, a higher spending power, and greater emphasis on transparent pricing by assessing measuring effects on the population. Related Books: - Pharmaceutical, Drugs, Proteins Technology Handbooks Active pharmaceutical ingredient (API), is the term that is used to refer to the biologically active component of a drug (e.g. tablet, capsule). A drug is usually composed of several components. The API represents the primary ingredient. Other ingredients are commonly known as "excipients. Sometimes a drug can contain several APIs and its effect on a patient depends on the dosage prescribed and can vary from person to person. In combination therapies, two or more than two active ingredients are used to treat different symptoms in different ways. Stringent quality control is a mandate when it comes to the manufacturing of drugs as the API represents the main component considered while making the prescription. The global active pharmaceutical ingredient market size is expected to reach a value of USD 286.6 billion by 2027, registering a CAGR of 6.7% over the forecast period. Factors, such as increasing preference for outsourcing APIs and growing prevalence of various target diseases such as cancer and Cardiovascular Diseases (CVDs) are expected to drive the market growth. Related Videos: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Pharmaceutical Drugs, Pharma Drug Ingredients Intermediates, Pharmaceutical Bulk Drugs The major factors driving the overall growth of the APIs market in this region include the growing incidence of preventable chronic diseases, increasing government focus on generic drugs, rising demand for biologics and specialty drugs, and technological advancements in the manufacturing processes of APIs. This market segment is expected to grow at a modest rate due to a combination of economic and healthcare severity measures and the introduction of low-cost, generic versions of branded drugs. Key Players:- Alpha Remedies Ltd. Ankur Drugs & Pharma Ltd. Aurobindo Pharma Ltd. Cian Healthcare Ltd Cipla Ltd. Dr. Reddy'S Laboratories Ltd. Farmson Pharmaceutical Gujarat Pvt. Ltd. Glaxosmithkline Pharmaceuticals Ltd. Indoco Remedies Ltd. Pan Drugs Ltd. Piramal Enterprises Ltd. Sanofi India Ltd. Sri Krishna Pharmaceuticals Ltd. Teva Pharmaceutical & Chemical Inds. India Pvt. Ltd. Triton Laboratories Ltd. Tags: - #APIBusiness #apimanufacturing #Apiproduction #APImarket #APIProject #ApiStartup #APIindustry #Activepharmaingredients #pharmaingredients #IndianPharma, #medicineingredients #CoronavirusBusiness #COVID2019 #Activepharmaingredientbusinessplan #APIbusinessplan #APIbusinessidea #startupAPIbusiness #Activepharmaingredientmanufacturing #APIproduction #API #Azithromycin #Cefixime #Telmisartan #Diclofenacsodium #Acecloflenac #DetailedProjectReport #businessconsultant #BusinessPlan #feasibilityReport #NPCS #entrepreneurindia #startupbusiness #startupbusinessideas #howtostartbusiness #InvestInStartups #Plan4Business #StartupProject #ProjectReport #startupplan #BusinessKaiseshurukare #BusinessProjectReport
Plant capacity: -Plant & machinery: -
Working capital: -T.C.I: -
Return: 1.00%Break even: N/A
Add to Inquiry Add to Inquiry Basket

Manufacturing of Ciprofloxacin Hydrochloride (CIPRO) - Active Pharma Ingredient

Manufacturing of Ciprofloxacin Hydrochloride (CIPRO) - Active Pharma Ingredient. Investment Opportunity for Startups and Entrepreneurs. Ciprofloxacin is an antibiotic agent in the fluoroquinolone class used to treat bacterial infections such as urinary tract infections and pneumonia. Ciprofloxacin is FDA approved for the treatment of urinary tract infections, sexually transmitted infections (gonorrhea and cancroid), skin, bone and joint infections, prostatitis, typhoid fever, gastrointestinal infections, lower respiratory tract infections, anthrax, plague, and salmonellosis. Related Projects: - Active Pharmaceutical Ingredient (API) Products, Bulk API Manufacturing Uses and Applications Ciprofloxacin only treats bacterial infections; it does not treat viral infections such as the common cold. For certain uses including acute sinusitis, lower respiratory tract infections and uncomplicated gonorrhea, ciprofloxacin is not considered a first-line agent. This antibiotic treats only bacterial infections. It will not work for virus infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections. Mycoplasma contamination is a major problem in cell culture in biomedical and biopharmaceutical research, with rates near 15-30%. While there is no method for visual confirmation of mycoplasma, contamination has serious effects on key characteristics and functions of cells, thus compromising any research done. Cipro (ciprofloxacin hydrochloride) is the standard antibiotic for rapid and efficient decontamination. Related Books: - Pharmaceutical, Drugs, Proteins Technology Handbooks CIPRO is indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. Ciprofloxacin (Cetraxal, Ciloxan, and Cipro) is an inexpensive drug used to treat certain bacterial infections. It is more popular than comparable drugs. Application Urogenital Infections Respiratory Tract Infections Gastrointestinal Infections Typhoid Bone and Joint Infections Skin and Soft Tissue Infections Sepsis and Other Systemic Infections Related Videos: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Pharmaceutical Drugs, Pharma Drug Ingredients Intermediates, Pharmaceutical Bulk Drugs Government Initiatives • Some of the initiatives taken by the Government to promote the pharmaceutical sector in India are as follows: • India plans to set up a nearly Rs 1 lakh crore (US$ 1.3 billion) fund to provide boost to companies to manufacture pharmaceutical ingredients domestically by 2023. • In November 2019, the Cabinet approved extension/renewal of extant Pharmaceuticals Purchase Policy (PPP) with the same terms and conditions while adding one additional product namely, Alcoholic Hand Disinfectant (AHD) to the existing list of 103 medicines till the final closure/strategic disinvestment of Pharma CPSUs. • Under Budget 2020-21, Rs 65,012 crore (US$ 9.30 billion) has been allocated to the Ministry of Health and Family Welfare is. The Government has allocated Rs 34,115 crore (US$ 4.88 billion) towards the National Health Mission under which rural and urban people will get benefited. • Rs 6,400 crore (US$ 915.72 million) has been allocated to health insurance scheme Ayushman Bharat – Pradhan Mantri Jan Arogya Yojana (AB-PMJAY). • As per Economic Survey 2019-20, Government expenditure (as a percentage of GDP) increased to 1.6 per cent in FY20 from 1.2 per cent in FY15 on health. Related Projects: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates • The National Health Protection Scheme is the largest Government funded healthcare programme in the world, which is expected to benefit 100 million poor families in the country by providing a cover of up to Rs 5 lakh (US$ 7,723.2) per family per year for secondary and tertiary care hospitalisation. The programme was announced in Union Budget 2018-19. • The Government of India is planning to set up an electronic platform to regulate online pharmacies under a new policy to stop any misuse due to easy availability. • Government of India unveiled 'Pharma Vision 2020' to make India a global leader in end-to-end drug manufacture. Approval time for new facilities has been reduced to boost investment. • India has imposed a provisional anti-dumping duty on imports of Ciprofloxacin Hydrochloride from China on the grounds that it was hurting domestic industry, following an investigation of the Directorate General of Trade Remedies (DGTR). • The department of revenue issued a notification to the effect on September 2, imposing a duty ranging between $0.94 and $3.29 per kg coming from China. • Ciprofloxacin Hydrochloride is used to treat different types of bacterial infections and certain types of diarrhea. The DGTR had initiated the investigation in January this year. Related Videos: - Industrial, Medical and Specialty Gases Manufacturing Project Ideas Market Outlook The India ciprofloxacin market is segmented based on composition, source, and form, route of administration, distribution channel, application, end user, company and region. Based on route of administration, the market can be categorized into oral, ophthalmic, optic, and intravenous and others. The intravenous segment is expected to witness significant growth through FY2026. This can be ascribed to the use of this route of administration for the drugs which are not absorbed after consumption through oral route. Additionally, large quantities of drug can be administered using this route of drug administration with 100% bioavailability. The Global Ciprofloxacin Market is growing at a faster pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2020 to 2027. Related Project:- Ciprofloxacin Hydrochloride Indian pharmaceutical sector is expected to grow to US$ 100 billion, while medical device market is expected to grow US$ 25 billion by 2025. Pharmaceuticals export from India stood at US$ 20.70 billion in FY20. Pharmaceutical export include bulk drugs, intermediates, drug formulations, biological, Ayush and herbal products and surgical. The remaining of the active pharmaceutical ingredient of ciprofloxacin is being dispersed in another combination product and specifically utilize in the urinary tract antibiotic only. Thereby anticipated to lure the new market players in the ciprofloxacin market. The higher incidence of skin and immunological disorder is anticipated to offer a steady revenue generation opportunity in the ciprofloxacin market. Increase awareness about safe drug utilization, however increase in adverse drug reaction awareness and stringent government impositions have narrowed the growth path for global Ciprofloxacin market in North America. Furthermore in East Asia region considerably higher market growth rate is expected due to higher utilization of ciprofloxacin in renal infection in the region. Thereby anticipated to increase the revenue generation in the Ciprofloxacin market. Related Projects: - Chemicals (Organic, Inorganic, Industrial) Projects The bulk drugs segment continues to be the highest revenue generating segment for the Indian pharma industry. It accounts for production worth Rs 120 bn and contributes about 36% of the total pharma exports. India produces 400 bulk drugs through its 1,300 licensed bulk drug units that cater to most of the domestic bulk drug requirements. Related Projects: - Active Pharma Ingredients(API) Key Players:- ? Aarti Drugs Ltd. ? Aurobindo Pharma Ltd. ? Cipla Ltd. ? Indoco Remedies Ltd. ? Kores (India) Ltd. ? Mylan Pharmaceuticals Pvt. Ltd. ? Neuland Laboratories Ltd. ? S S Organics Ltd ? Smruthi Organics Ltd. ? Sreepathi Pharmaceuticals Ltd. ? Sterling Basic Organics Ltd. ? Sun Pharma Laboratories Ltd. ? Sun Pharma Medisales Pvt. Ltd. ? Wockhardt Ltd. Tags:- #CiprofloxacinHydrochloride #Ciprofloxacin #CiprofloxacinBusinessPlan #activepharmaceuticalingrediants #activepharmaingredient #Pharmaceutical #pharmaindustry #APIManufacturing #APIProduction #APImarket #APIBusiness #APIbusinessplan #startupAPIbusiness #CIPRO #startyourbusiness #investmentopportunity #covidbusiness #DetailedProjectReport #businessconsultant #BusinessPlan #feasibilityReport #NPCS #bussinessplanshub #Startupbusiness4you #StartupBusinessPlan #startupinvestment #startup #ChemicalIndustry
Plant capacity: -Plant & machinery: -
Working capital: -T.C.I: -
Return: 1.00%Break even: N/A
Add to Inquiry Add to Inquiry Basket

Automated Vehicle Scrapping and Recycling Unit

Automated Vehicle Scrapping and Recycling Unit What is Auto Shredding? The scrapping of cars and large household equipment is a method where the components fed into it are grinded to fist-size bits by a hammer mill. A combination of ferrous material, non-ferrous metal (e.g. copper and aluminium alloys), and shredding scrap, called vehicle shredder remnants of automotive shredder residue, resulted in the shredding of vehicles (ASR). ASR is made up of glass, fabric, rubber, liquids for vehicles, plastics, and soil. Often ASR is divided into dust and shredder in small proportion. These leftover materials are considered 'Car-fluff' occasionally. Related Projects: - Waste Management and Recycling At such a time when different economies run solely on recycled car scrap, India, the’s greatest economy, has consumed an excessive amount of time to enter the market. Not only is scrap production a big-buck making industry from car recycling, but it also coincides with the additional advantage of being environmentally sustainable by getting the old polluting cars off the roads. Nevertheless, it has become evident, despite the odd regulation, that India is firmly interested in making attempts to mitigate air pollution and preserve the environment. Related Books:- Products From Waste, Automobile, Leisure, Entertainment, Ware Housing & Real Estate Projects, Greases, Hospitality, Medical, Infrastructure, Lubricants, Petro Chemicals, Petroleum, Waste Management, Recycling Scrap Import in India Overview At 60.6 kg per capita, India's demand for steel is increasing, relative to over 400 kg per capita in developing countries. The need for steel is key to various urban/rural infrastructure projects implemented by the government and private sectors. The Indian steel sector contributes 50 percent of the share of secondary steel. As ferrous scrap is one of the major raw materials for secondary steel production units, India's steel scrap demand is around 16-18 mnt pa. Of this necessity, it imports around 1/3rd of the content. In India, scrap imports have seen a gradual rise in the last few years India's FY16 scrap supply stood at 6.2 mnt, a rise of 12.7% from 5.5 mnt of material imported in FY15. With the Make in India project eyeing 300 mnt steel capacity, raw material requirements are likely to expand. The inclusion of indigenous scrap from auto-shredding would place Indian producers in a position of benefit, considering the existing demand for scrap in India. In recent times, India witnessed its 18th bulk scrap shipments in 2016. The demand for raw materials is increasing gradually. Scrap Metal Recycling Business Possibility: Waste metals consist of many metals, with the exception of precious metals, such as iron, steel, copper, brass, aluminium, alloy, nickel, bronze, and many more. After multiple applications, such as in processing factories that produce utensils, frames, and various items utilizing these metals, these materials are left untouched as waste. Such metal waste arrives in big quantities and is very beneficial. Compared to some other recycling firm, what allows the metal recycling industry so much in popularity is the returns it provides. Related Books:- Waste Management, Waste Disposal And Recycling Industry You need to consider what you're going to recycle before you begin the business. To know precisely what is like to be in this market, it is therefore important to perform a viability study test. There are several benefits and drawbacks of this business, certain problems, and problems that fall in between that one wants to get an understanding about. Here's a short, thorough business strategy for metal recycling. What is needed to start the Business of Recycling? • Recycling plant: You need to have a factory which you build your recycling plant after deciding what kind of metal you are going to recycle and at what level. Consequently, since you recycle metal, you require an open area that is fairly large to construct the recycling facility, stock scrap metal, tools, machinery, and finished goods. Recycling metal is called a heavy industry task, so you must have a space-like warehouse. Projects: - Project Reports & Profiles • Infrastructure: To help your business, you ought to provide some decent infrastructure A locked area where the computers are going to work. The location in which you are going to bring your recycled products, the area where you are going to separate metals, disinfect them, and so on. You will need a vented room that suits a typical factory layout. Build the infrastructure for security concerns to the requirements of a factory. • Metal Scrap: Join forces with scrap pickers, scrap dealers, landowners, and their likes to have the sum of metal scrap needed. Test it with independent scrap laborers as they can supply you with the scrap at a very low rate relative to a regular scrap dealer. If the need is immense, you should approach wholesalers selling metal waste. • Equipment: You must have all the requisite recycling equipment, such as tanks, compressors, grinders, refiners, heating tools, etc. It would be safer if you got the new equipment since the modern equipment will be extremely efficient, and not traditional. Books:- BOOKS & DATABASES • Machinery Required: You ought to get the recycling system that is needed. There is usually no particular disposal machine for metal fragments since it is performed in separate phases. For instance, a separation machine, cleaner, melting machine, grinding machine, container forming, cooling field, etc. are needed. • Man Power: You do need human energy to function in your factory while being surrounded by so many robots. First, you ought to employ a specialist to guide your recycling venture since he would be well acquainted with the recycling work. You need any labor besides him, depending on the necessity. You will need to provide them with previous scrap metal plant experience. • Utilities: You require simple infrastructure like power link, water supply, transit system to convey recycled materials, better highways, plant at a required and chosen spot, and so on, much like every other plant. There could be other requirements that you might just have to look into in a scrap metal business cantered on the location wherever you want to operate your business. Market Research: - Market Research Report • Documents and permission: You are going to begin a company for metal recycling that can be further used by producers. You therefore ought to get licenses from various agencies. First of all, you ought to have a document for a metal recycling facility where you must even state which kind of material you are trying to reuse. Private Company Involvement Although MSTC's change is a positive step, it might not be a smart option to route every scrap supply into MSTC solely. Private sector engagement must be promoted. A combination of competition-based private and public sector employees would be more effective. Related Videos: - Business Ideas for Startups In the end, the automotive recycling industry in India portrays a tremendous opportunity for scrap production in the face of all the commitments and challenges. The use of scrap in steelmaking would lead to the steel cycle economy. India, as a developing world wants long-term opportunities to plug into such renewable, productive industries. India's Auto Shredding Kick Start-MSTC and Mahindra Intertrade JV In the freshly drafted MoU, MSTC Limited, a Mini Ratna Category-I PSU underneath the administrative jurisdiction of the Ministry of Steel, the Government of India, and Mahindra Intertrade Limited (MIL), combined forces to established India's first auto shredding factory. Related Videos:- Small Business Ideas The plant would be the first in the world to construct such auto shredding units in the series. In the Make in India initiative, India's foraying into the car shredding market is also a generation ahead. Can car recycling in India, become the next US, Europe, or China? The US, Europe, and China are the world's biggest and most mature auto-recycling industries. From as far back as the 1970s, as in the situation of the US, these nations have been destroying old cars. It is very well known that these are industries focused on waste and the justification for this is auto recycling. In the US, vehicle recycling dates back to the 1970s, while in the 2000s, Europe and Japan started recycling, followed by China in 2012. In developing countries, the overall industry value of car scraping is about 30+ million vehicles, producing about 27 million tonnes of waste. Vehicle Recycling Scope in India As India is the world's third-largest steelmaker, there is a tremendous opportunity for auto-recycling. India's car recycling will bring various advantages to the nation, ranging from a drive to fuel-saving and job growth in the automotive field. 25 percent (7 million vehicles) of the estimated cars that may originally be scrapped are projected to produce roughly USD 2.9 billion (analogous to ~INR 190 billion) in business. Such statistics are expected to rise with time. A car weights 1,400-1,600 kg on average. It contains 65-70% steel scrap, 7-8% aluminium scrap, 1-1.5% copper scrap and 15-20% rubber and plastic scrap upon recycle. A recycled car will earn approximately INR 30.000-35.000 at existing scrap rates (USD 380-455). It has the capacity to produce about 6 million tonnes (mnt) of waste, ~150,000 mt of copper scrap, ~0.8 mnt of aluminum scrap, and ~1.8 mnt of plastic and rubber scrap, considering 20-25% of vehicles are discarded in the first year. It is predicted that statistics will rise in the years ahead. Car Recycling Market Prospects In both the automobile and steel sectors, the car recycling market is a large sector with a strong market for End of Life Vehicles (ELV). The CEO of the Association of Automotive Recyclers (ARA), Michael E. Wilson, claims that both the prospects and the value of the automotive recycling market are increasing rapidly. These days, there are different opportunities for junk vehicle owners to sell their junk cars for money. On Craigslist, eBay and even directly to scrap yards and vehicle dealers, they will market their scrap vehicles. Scrap yards and car dealers bid at the very same time for EOL vehicles sold on Craigslist, eBay, or directly from holders of scrap cars. Businesses ought to guarantee that they are fitted with the newest equipment in the industry and meet ARA-specified requirements for auto reuse activities Voluntary scrapping of old cars is proposed by Union Budget 2021-22 It is focused on health tests for personal vehicles over 20 years and for commercial vehicles over 15 years. For the automotive industry that has been waiting for a 'Scrappage Scheme' for the past decade, this is a welcome change. Constructing every industry from zero is a challenging job, and before actually achieving profitability, it must forehead different obstacles. For every country, when an initiative of this size is hired to work, the position of its people is vital. Whereas the government can take this step to grow the business, the people of the country who want to make deliberate attempts to protect and preserve the ecosystem by giving up their old vehicles are still a major part of the obligation. Union Minister Nitin Gadkari said the strategy would contribute to approximately 10,000 crores of new investment and generate as many as 50,000 jobs. It is projected that such cars cause 10-12 times greater emissions than the new vehicles. Highlighting the policy's advantages, Gadkari said it would lead to scrap metal recycling, better protection, reduced air pollution, lower oil imports due to higher fuel consumption of existing vehicles, and encourage investment. Recycled content from old cars would further lower costs, adding that the turnover of the automotive sector, which is Rs. 4.5 lakh crore with exports of Rs. 1.45 lakh crore, will have a lift. Bottom Line The scrapping strategy would improve car purchases in the country as a fresh one will certainly be purchased by the one scrapping the vehicle. All in all, the Scrappage Program aims to help incorporate Rs 10,000 crore worth of fresh investment and generate 50,000 new employment options. The Scrappage Program would improve car purchases in the nation as a fresh one will definitely be purchased by the one scrapping the vehicle. Overall, with the green flagging off the “Scrappage Policy”, the business is likely to hike up in the coming days and the business investment is not going to let anyone down. Voluntary car scrapping scheme to drive out old and obsolete cars, not only helping to curb emissions, but also reducing the fuel import bills of India. All in, the Scrappage Program aims to help incorporate Rs 10,000 crore worth of fresh expenditure and add 50,000 new work prospects. NPCS is best known for providing a project report for its clients. All the project report covers detailed aspects of the business from analysing the market, confirming availability of various necessities such as plant & machinery, raw materials to forecasting the financial requirements. You can get in touch with the NPCS team through the official website and get benefited from the books and project reports provided by us. Tags:- #AutomatedVehicleScrappingandRecycling #RecyclingUnit #AutomatedVehicle #AutomatedVehicleRecycling #WasteManagement #EwasteManagement #WasteManagementIndustry #WasteRecyclingBusiness #WasteManagementMarket #RecyclingUnitBusiness #AutomatedVehicleScrapping #InvestInStartups #StartupIndiaConsultants #Plan4Business #StartupPlan #StartupIdea #DetailedProjectReport #businessconsultant #BusinessPlan #feasibilityReport #NPCS #industrialproject #entrepreneurindia #startupbusiness #IndustrialWasteManagement
Plant capacity: -Plant & machinery: -
Working capital: -T.C.I: -
Return: 1.00%Break even: N/A
Add to Inquiry Add to Inquiry Basket

Information
  • One Lac / Lakh / Lakhs is equivalent to one hundred thousand (100,000)
  • One Crore is equivalent to ten million (10,000,000)
  • T.C.I is Total Capital Investment
  • We can modify the project capacity and project cost as per your requirement.
  • We can also prepare project report on any subject as per your requirement.
  • Caution: The project's cost, capacity and return are subject to change without any notice. Future projects may have different values of project cost, capacity or return.

Add multiple items to inquiry
Select the items and then press Add to inquiry button

Page 15 of 56 | Total 551 projects in this category
« Previous   Page 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 .... 55 56   Next »

About NIIR PROJECT CONSULTANCY SERVICES

Hide »

NIIR PROJECT CONSULTANCY SERVICES (NPCS) is a reliable name in the industrial world for offering integrated technical consultancy services. NPCS is manned by engineers, planners, specialists, financial experts, economic analysts and design specialists with extensive experience in the related industries.

Our various services are: Detailed Project Report, Business Plan for Manufacturing Plant, Start-up Ideas, Business Ideas for Entrepreneurs, Start up Business Opportunities, entrepreneurship projects, Successful Business Plan, Industry Trends, Market Research, Manufacturing Process, Machinery, Raw Materials, project report, Cost and Revenue, Pre-feasibility study for Profitable Manufacturing Business, Project Identification, Project Feasibility and Market Study, Identification of Profitable Industrial Project Opportunities, Business Opportunities, Investment Opportunities for Most Profitable Business in India, Manufacturing Business Ideas, Preparation of Project Profile, Pre-Investment and Pre-Feasibility Study, Market Research Study, Preparation of Techno-Economic Feasibility Report, Identification and Selection of Plant, Process, Equipment, General Guidance, Startup Help, Technical and Commercial Counseling for setting up new industrial project and Most Profitable Small Scale Business.

NPCS also publishes varies process technology, technical, reference, self employment and startup books, directory, business and industry database, bankable detailed project report, market research report on various industries, small scale industry and profit making business. Besides being used by manufacturers, industrialists and entrepreneurs, our publications are also used by professionals including project engineers, information services bureau, consultants and project consultancy firms as one of the input in their research.

^ Top